Liver-specific thyroid hormone receptor-β agonism alleviates alcoholic steatohepatitis (ASH) in mice

• Published in: Biochemical and biophysical research communications 2024-11, Vol.734, p.150742, Article 150742
• Main Authors: Shahi, Ambuj, Yadav, Abhishek, Rajak, Sangam, Raza, Sana, Tewari, Archana, Gupta, Pratima, Sinha, Rohit A.
• Format: Article
• Language: English
• ISSN: 0006-291X; 1090-2104; 1090-2104
• DOI: 10.1016/j.bbrc.2024.150742

Alcoholic steatohepatitis (ASH) represents a critical stage in alcoholic liver disease (ALD), which significantly increases the risk of developing alcoholic hepatitis and cirrhosis. Currently, corticosteroids and alcohol abstinence remain the only available strategy to prevent or reverse ASH progression with no FDA approved drug therapy till date. Given the notable pathological similarities between ASH and metabolic dysfunction-associated steatohepatitis (MASH), repurposing drugs approved for MASH presents an attractive therapeutic approach to treat ASH. In this context, we evaluated the efficacy of Resmetirom, a recently approved drug for MASH, in a mouse model of ASH. Our findings demonstrate that Resmetirom, a liver-specific thyroid hormone analog, not only reduces hepatic steatosis but also markedly alleviates liver injury, oxidative stress, and inflammation associated with ASH. In summary, this study provides a proof-of-concept for the potential use of MASH drugs in treating ASH and establishes a foundation for future testing and clinical trials of Resmetirom, in patients with ASH. •Resmetirom attenuates alcohol-induced hepatic steatosis in mice.•Resmetirom mitigates alcohol-induced liver injury in mice.•Resmetirom ameliorates alcohol-induced hepatic oxidative stress and inflammation in mice.